# PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

> **NCT06172127** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MedSIR** · enrollment: 165 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Trastuzumab deruxtecan
- **DRUG:** Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection
- **DRUG:** Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection

## Key facts

- **NCT ID:** NCT06172127
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-22
- **Primary completion:** 2027-04
- **Final completion:** 2029-06
- **Target enrollment:** 165 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06172127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06172127, "PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06172127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*